Navigation Links
Results of the Annual General Meeting Held on September 24, 2008
Date:9/24/2008

DUBLIN, Ireland, September 24 /PRNewswire-FirstCall/ -- Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that at its Annual General Meeting today, all resolutions contained in the notice of meeting were duly passed and the results of the poll are as follows:

For* Against Withheld**

1. To elect Mr Matthew 301,376,910 4,696,170 25,441,808

Emmens as a Director

of the Company

2. To elect Mr Angus 331,225,599 138,229 151,060

Russell as a

Director of the

Company

3. To elect Mr Graham 331,234,635 127,173 153,080

Hetherington as a

Director of the

Company

4. To elect Dr Barry 328,858,454 2,501,778 154,656

Price as a Director

of the Company

5. To elect Mr David 330,945,634 412,470 156,784

Kappler as a

Director of the

Company

6. To elect Dr Jeffrey 331,221,109 138,828 154,951

Leiden as a Director

of the Company

7. To elect Mr Patrick 330,949,493 412,089 153,306

Langlois as a

Director of the

Company

8. To elect Ms Kate 331,014,606 346,949 153,333

Nealon as a Director

of the Company

9. To elect Mr David 327,884,774 2,101,928 1,528,186

Mott as a Director

of the Company

10. To elect Dr Michael 331,232,603 126,815 155,470

Rosenblatt as a

Director of the

Company

11. To re-appoint 327,634,578 1,301,388 2,578,922

Deloitte & Touche

LLP as Auditors of

the Company

12. To authorise the 331,225,599 1,470,679 159,584

Audit, Compliance

and Risk Committee

to determine the

remuneration of the

Auditors

13. To authorise the 328,104,104 3,189,130 221,654

allotment of shares

14. To authorise the 329,760,418 1,575,955 178,515

disapplication of

pre-emption rights

15. To authorise market 330,598,450 729,745 186,693

purchases

16. To change the name 331,323,817 31,609 159,462

of the Company to

Shire plc

Notes to Editors

Shire Limited Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

For further information please contact:

Investor Relations Clea Rosenfeld (Rest of the World) +44-1256-894-160

Eric Rojas (North America) +1-484-595-8252

Media Jessica Mann (Rest of the World) +44-1256-894-280

Matthew Cabrey (North America) +1-484-595-8248

Jessica Cotrone (North America) +1-617-613-4640


'/>"/>
SOURCE Shire Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. CNS Response Announces Fiscal Third Quarter 2007 Results
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Martek to Announce Third Quarter 2007 Results on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer and recently ... have entered into a multiyear collaboration to identify and characterize novel CRISPR-Cas nucleases. ... for gene editing across all applications. , Under the terms of the agreement, ...
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, ... and biotechnology industries to improve patient outcomes and quality of life, will now ... testing are being attributed to new regulatory requirements for all new drug products, ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... today it will be hosting a Webinar titled, “Pathology is going digital. Is ... , on digital pathology adoption best practices and how Proscia improves lab economics ...
Breaking Biology Technology:
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
Breaking Biology News(10 mins):